discuss NordICC with the trial PI
Power calc specified 50% non-adherence
ADR is on par with US studies from the time
Colo quality good
Perf rate lower than US!
How does he counsel individuals & governments
What he thinks of USPSTF

5.22 NordICC trial interview with PI Michael Bretthauer - Offer but don't Nudge

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

5.22 NordICC trial interview with PI Michael Bretthauer - Offer but don't Nudge

Download our free app to listen on your phone